Autologous NY-ESO-1-targeting dendritic cell vaccine (Roswell Park Cancer Institute)

N/A

Report date: 2024/09/27 20:00:43

Base Information

Drug NameAutologous NY-ESO-1-targeting dendritic cell vaccine (Roswell Park Cancer Institute)
Drug Alias Name自体NY-ESO-1靶向树突细胞疫苗-美国国家罗斯维尔公园癌症研究所ALVAC(2)-NY-ESO-1 (M)/TRICOMDEC-205-NY-ESO-1vCP2292VCP-2292
ClassificationVaccines > Development/production technology > Dendritic cell vaccineCell and gene therapy > Cell therapy > Immune system cell therapy > Dendritic cell therapy > Dendritic cell vaccine
Mechanisms of ActionNY-ESO-1 gene transferenceImmunostimulants
TargetsCancer/testis antigen 1
Therapy Area/IndicationsFallopian Tube NeoplasmsOvarian NeoplasmsColorectal Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesRoswell Park Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesRoswell Park Cancer InstituteLudwig Institute For Cancer Research
Active IndicationsN/A
Inactive IndicationsFallopian Tube NeoplasmsOvarian NeoplasmsColorectal Neoplasms +[7] 

Other Information

ATC CodeN/A
Related LinksN/A